Jeff Hackman

“I think, Ram, just to add on to that, and we recently had a patient, a mother come talk to us whose son was treated with cisplatin and it sticks with you when you have these conversations with these patients who had to fight for, for example, having a supportive care product like this to be administered.”

“We are encouraged by our strong start to the year and believe 2026 is a defining period for Fennec. Our conviction is rooted in the progress across many multiple fronts.”

“Boy, it's hard to believe it's been one year since I stepped in into the CEO role here at Fennec. You know, when I joined, my focus was clear. I wanted to stabilize the business, sharpen our strategy, and build a strong foundation for sustainable growth.”

“I wanted to thank you all for joining us today as we review our first quarter performance and share the outlook for the year ahead. I'm excited to share the details and highlights of our results for Q1 in 2025.”

“Today I'm going to discuss our continued progress, including updates on our market expansion efforts, new academic endorsements, our new demographic interest, our educational investments, our operating efficiency and our strong overall execution.”